天境生物上涨19.41%，报2.03美元/股，总市值1.66亿美元

Core Insights - Tianjing Bio (IMAB) opened with a significant increase of 19.41% on July 31, reaching a price of $2.03 per share, with a trading volume of $3.75 million and a total market capitalization of $166 million [1] - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Company Overview - Tianjing Bio is an offshore holding company registered abroad, operating through its domestic subsidiary Tianjing Bio, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2] - The company aims to develop innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential globally, addressing unmet clinical needs and improving the quality of life for patients worldwide [2] - Tianjing Bio is striving to become a leading biopharmaceutical company rooted in China and oriented towards global markets [2]